aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression
January 25 2021 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that it will present a
poster and participate in a live Q&A session at the Virtual
Keystone Symposia: Tumor Metabolism and the Microenvironment, which
is being held January 25 – 28, 2021. The abstract and poster are
available on the Keystone Symposia website.
The poster presents preclinical findings
demonstrating that Neuropilin-2 (NRP2) was highly expressed on key
immune cells implicated in regulating cancer progression, including
myeloid derived suppressor cells (MDSCs), tumor associated
macrophages (TAMs) generated from triple negative breast cancer
cell lines, mature dendritic cells (DCs), and inducible T
regulatory cells (Tregs). Further research showed that MDSCs and
TAMs suppressed T cell proliferation and activation.
Details of the abstract and poster presentation
are as follows:
Title: Neuropilin-2 is
Expressed on Immune Cells Present in the Tumor Microenvironment,
and May Contribute to the Suppression of Immune Regulation Leading
to Progression and Metastasis of CancerAuthors:
Samantha Tyler, Michaela Ferrer, Clara Polizzi, Rodrigo Da Silva,
Lisa Eide, Kendall Walwick, Matt Seikkula, Christoph Burkart,
Suzanne Paz, Leslie Nangle. aTyr Pharma, San Diego,
CA.Session: Poster Session 2Live Q&A
Date and Time: January 27, 2021, 4:00 – 5:00PM EST
The poster is also available on the aTyr
website.
“As we continue to explore the role of NRP2 in
the progression of certain aggressive tumors, we are pleased to
demonstrate for the first time that NRP2 is highly expressed on key
immune cells in the tumor microenvironment that are implicated in
regulating the progression of tumors and their metastasis,” said
Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer
of aTyr. “These findings support the potential of NRP2 as a target
for cancer therapeutics, possibly through the immune regulation of
the tumor microenvironment. Our panel of highly specific antibodies
selectively targeting NRP2, such as our lead IND candidate
ATYR2810, may present differentiated approaches to treating certain
aggressive cancers where NRP2 is implicated.”
About NRP2
Neuropilin-2 (NRP2) is a cell surface receptor
that plays a key role in lymphatic development and in regulating
inflammatory responses. In many forms of cancer, high NRP2
expression is associated with worse outcomes. NRP2 can interact
with multiple ligands and co-receptors through distinct domains to
influence their functional roles, making it a potential drug target
with multiple distinct therapeutic applications. NRP2 interacts
with type 3 semaphorins and plexins to impact inflammation and with
forms of vascular endothelial growth factor (VEGF) and their
receptors, to impact lymphangiogenesis. In addition, NRP2 modulates
interactions between CCL21 and CCR7 potentially impacting homing of
dendritic cells to lymphoid organs. aTyr is currently investigating
NRP2 receptor biology, both internally and in collaboration with
key academic thought leaders, as a novel target for new product
candidates for a variety of diseases, including cancer and
inflammation.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“seeks,” “should,” “will,” and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by such safe harbor provisions for forward-looking
statements and are making this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
include statements regarding potential therapeutic benefits and
applications of NRP2 antibodies, including ATYR2810; timelines and
plans with respect to certain development activities (such as the
timing of data from clinical trials); and certain development
goals. These forward-looking statements also reflect our current
views about our plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to us and on assumptions we have made. Although we believe that our
plans, intentions, expectations, strategies and prospects, as
reflected in or suggested by these forward-looking statements, are
reasonable, we can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved. All
forward-looking statements are based on estimates and assumptions
by our management that, although we believe to be reasonable, are
inherently uncertain. Furthermore, actual results may differ
materially from those described in these forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control including, without limitation, uncertainty
regarding the COVID-19 pandemic, risks associated with the
discovery, development and regulation of our product candidates,
the risk that we or our partners may cease or delay preclinical or
clinical development activities for any of our existing or future
product candidates for a variety of reasons (including difficulties
or delays in patient enrollment in planned clinical trials), the
possibility that existing collaborations could be terminated early,
and the risk that we may not be able to raise the additional
funding required for our business and product development plans, as
well as those risks set forth in our most recent Annual Report on
Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC
filings. Except as required by law, we assume no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Contact:Ashlee DunstonDirector,
Investor Relations and Corporate
Communicationsadunston@atyrpharma.com
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Aug 2024 to Sep 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Sep 2023 to Sep 2024